Products - Blood and bone marrow cancers | Topic | NICE

Showing 6 products

Date | Title

Status: In consultationRemove ‘Status: In consultation’ filter

Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
21 January 2026
Expected publication date:
11 February 2026
Suspected Cancer: recognition and referral (update)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
2 February 2026
Expected publication date:
25 March 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
30 January 2026
Expected publication date:
13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
4 February 2026
Expected publication date:
13 May 2026
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
11 February 2026
Expected publication date:
TBC
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
11 February 2026
Expected publication date:
TBC